| Ref # | Hits | Search Query | DBs | Default Operator | Plurals | Time Stamp |
|---|---|---|---|---|---|---|
| L1 | 1520 | (546/141,142,143,144).CCLS. | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | OFF | 2005/10/15 14:37 |
| L2 | 980 | (514/309,310).CCLS. | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | OFF | 2005/10/15 14:37 |
| L3 | 29 | Amy.inv. and Bunker.inv. | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | OFF | 2005/10/15 14:38 |
| L4 | 36 | Daniel.inv. and Ortwine.inv. | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | OFF | 2005/10/15 14:38 |

| Ref # | Hits | Search Query | DBs | Default Operator | Plurals | Time Stamp |
|---|---|---|---|---|---|---|
| L1 | 1520 | (546/141,142,143,144).CCLS. | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | OFF | 2005/10/15 14:37 |
| L2 | 980 | (514/309,310).CCLS. | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | OFF | 2005/10/15 14:37 |
| L3 | 29 | Amy.inv. and Bunker.inv. | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | OFF | 2005/10/15 14:38 |
| L4 | 36 | Daniel.inv. and Ortwine.inv. | US-PGPUB; USPAT; EPO; JPO; DERWENT | OR | OFF | 2005/10/15 14:38 |

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1611bxv

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

| | | | |
|---|---|---|---|
| NEWS | 1 | | Web Page URLs for STN Seminar Schedule - N. America |
| NEWS | 2 | | "Ask CAS" for self-help around the clock |
| NEWS | 3 | JUL 20 | Powerful new interactive analysis and visualization software, STN AnaVist, now available |
| NEWS | 4 | AUG 11 | STN AnaVist workshops to be held in North America |
| NEWS | 5 | AUG 30 | CA/CAplus -Increased access to 19th century research documents |
| NEWS | 6 | AUG 30 | CASREACT - Enhanced with displayable reaction conditions |
| NEWS | 7 | SEP 09 | ACD predicted properties enhanced in REGISTRY/ZREGISTRY |
| NEWS | 8 | OCT 03 | MATHDI removed from STN |
| NEWS | 9 | OCT 04 | CA/CAplus-Canadian Intellectual Property Office (CIPO) added to core patent offices |
| NEWS | 10 | OCT 06 | STN AnaVist workshops to be held in North America |
| NEWS | 11 | OCT 13 | New CAS Information Use Policies Effective October 17, 2005 |

| | |
|---|---|
| NEWS EXPRESS | JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005 |
| NEWS HOURS | STN Operating Hours Plus Help Desk Availability |
| NEWS INTER | General Internet Information |
| NEWS LOGIN | Welcome Banner and News Items |
| NEWS PHONE | Direct Dial and Telecommunication Network Access to STN |
| NEWS WWW | CAS World Wide Web Site (general information) |

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:14:35 ON 15 OCT 2005

=> file reg

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 0.21 | 0.21 |

FILE 'REGISTRY' ENTERED AT 14:14:41 ON 15 OCT 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 14 OCT 2005 HIGHEST RN 865347-39-3
DICTIONARY FILE UPDATES: 14 OCT 2005 HIGHEST RN 865347-39-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

**********
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
**********

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Documents and Settings\VBalasubramania\My Documents\STNEXP4\QUERIES\10634473-3.str




chain nodes :
11 13 14 18 19
ring nodes :
1 2 3 4 5 6 7 8 9 10
chain bonds :
3-11 7-18 8-19 11-13 13-14
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10
exact/norm bonds :
3-11 5-7 6-10 7-8 7-18 8-9 8-19 9-10 11-13 13-14
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :
containing 1 :

G1:C,O,S,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 13:CLASS 14:Atom 18:CLASS 19:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR




G1 C,O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam
SAMPLE SEARCH INITIATED 14:15:05 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 6742 TO ITERATE

29.7% PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 129918 TO 139762
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 sss ful
FULL SEARCH INITIATED 14:15:27 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 133924 TO ITERATE

100.0% PROCESSED 133924 ITERATIONS 123 ANSWERS
SEARCH TIME: 00.00.06

L3 123 SEA SSS FUL L1

```
=> file caplus
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                       161.76     161.97

FILE 'CAPLUS' ENTERED AT 14:15:39 ON 15 OCT 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 15 Oct 2005  VOL 143 ISS 17
FILE LAST UPDATED: 14 Oct 2005  (20051014/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4            9 L3

=> d l4 1-9 bib hitstr

L4   ANSWER 1 OF 9  CAPLUS  COPYRIGHT 2005 ACS on STN
AN   2005:17019  CAPLUS
DN   142:107448
TI   Combination of an allosteric inhibitor of matrix metalloproteinase-13 and
     a ligand to an alpha-2-delta receptor
IN   Roark, William Howard
PA   Warner-Lambert Company LLC, USA
SO   U.S. Pat. Appl. Publ., 44 pp.
     CODEN: USXXCO
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     ---------------     ----   --------    --------------------    --------
PI   US 2005004177        A1    20050106    US 2004-883899          20040702
     WO 2005002585        A1    20050113    WO 2004-IB2075          20040621
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
             SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
             SN, TD, TG
```

PRAI US 2003-484577P P 20030702
OS MARPAT 142:107448
IT **724707-70-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(combination of allosteric inhibitor of MMP-13 and ligand to alpha-2-delta receptor for treatment of joint disorders)
RN 724707-70-4 CAPLUS
CN Benzoic acid, 4-[[7-[[(4-methoxyphenyl)acetyl]amino]-1-oxo-2(1H)-isoquinolinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT **724707-68-0P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(combination of allosteric inhibitor of MMP-13 and ligand to alpha-2-delta receptor for treatment of joint disorders)
RN 724707-68-0 CAPLUS
CN Benzoic acid, 4-[[7-[[(4-methoxyphenyl)acetyl]amino]-1-oxo-2(1H)-isoquinolinyl]methyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:589249 CAPLUS
DN 141:123653
TI Preparation of quinazolinyl amides and esters as matrix metalloproteinase inhibitors
IN Bunker, Amy Mae; Picard, Joseph Armand
PA USA
SO U.S. Pat. Appl. Publ., 51 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | US 2004142950 | A1 | 20040722 | US 2003-739261 | 20031218 |
| | CA 2513115 | AA | 20040805 | CA 2004-2513115 | 20040106 |
| | WO 2004064842 | A1 | 20040805 | WO 2004-IB23 | 20040106 |

W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG,

ES, ES, FI, FI, GB, GD, GE, GE, GH, GH, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ

PRAI US 2003-440837P P 20030117
WO 2004-IB23 W 20040106

OS MARPAT 141:123653

IT **724707-67-9P**, 4-[[7-[[2-(3-Methoxyphenyl)acetyl]amino]-1-oxo-1H-isoquinolin-2-yl]methyl]benzoic acid **724707-68-0P**, 4-[[7-[[2-(4-Methoxyphenyl)acetyl]amino]-1-oxo-1H-isoquinolin-2-yl]methyl]benzoic acid **724707-71-5P**, 4-[[7-[[2-(3-Fluorophenyl)acetyl]amino]-1-oxo-1H-isoquinolin-2-yl]methyl]benzoic acid **724707-72-6P**, 4-[[7-[[2-(4-Fluorophenyl)acetyl]amino]-1-oxo-1H-isoquinolin-2-yl]methyl]benzoic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(MMP-13 inhibitor; preparation of quinazolinyl and isoquinolinyl amides and esters as MMP-13 inhibitors for treatment of breast cancer, cartilage damage, rheumatoid arthritis, and osteoarthritis)

RN 724707-67-9 CAPLUS
CN Benzoic acid, 4-[[7-[[(3-methoxyphenyl)acetyl]amino]-1-oxo-2(1H)-isoquinolinyl]methyl]- (9CI) (CA INDEX NAME)




RN 724707-68-0 CAPLUS
CN Benzoic acid, 4-[[7-[[(4-methoxyphenyl)acetyl]amino]-1-oxo-2(1H)-isoquinolinyl]methyl]- (9CI) (CA INDEX NAME)




RN 724707-71-5 CAPLUS
CN Benzoic acid, 4-[[7-[[(3-fluorophenyl)acetyl]amino]-1-oxo-2(1H)-isoquinolinyl]methyl]- (9CI) (CA INDEX NAME)




RN 724707-72-6 CAPLUS
CN Benzoic acid, 4-[[7-[[(4-fluorophenyl)acetyl]amino]-1-oxo-2(1H)-

isoquinolinyl]methyl]- (9CI) (CA INDEX NAME)



IT **724707-70-4P**, 4-[[7-[[2-(4-Methoxyphenyl)acetyl]amino]-1-oxo-1H-isoquinolin-2-yl]methyl]benzoic acid tert-butyl ester
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of quinazolinyl and isoquinolinyl amides and esters as MMP-13 inhibitors for treatment of breast cancer, cartilage damage, rheumatoid arthritis, and osteoarthritis)
RN 724707-70-4 CAPLUS
CN Benzoic acid, 4-[[7-[[(4-methoxyphenyl)acetyl]amino]-1-oxo-2(1H)-isoquinolinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:615576 CAPLUS
DN 137:169431
TI Preparation of isoquinolinones as dipeptidyl peptidase IV inhibitors for the prophylaxis or treatment of diabetes
IN Oi, Satoru; Ikedou, Koji; Takeuchi, Koji; Ogino, Masaki; Banno, Yoshihiro; Tawada, Hiroyuki; Yamane, Taihei
PA Takeda Chemical Industries, Ltd., Japan
SO PCT Int. Appl., 600 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI WO 2002062764 | A1 | 20020815 | WO 2002-JP831 | 20020201 |
| WO 2002062764 | C2 | 20021010 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2437492 | AA | 20020815 | CA 2002-2437492 | 20020201 |

| | | | | | |
|---|---|---|---|---|---|
| | JP 2003238566 | A2 | 20030827 | JP 2002-26185 | 20020201 |
| | EP 1355886 | A1 | 20031029 | EP 2002-711278 | 20020201 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| | CN 1500080 | A | 20040526 | CN 2002-807429 | 20020201 |
| | BR 2002006831 | A | 20040706 | BR 2002-6831 | 20020201 |
| | NO 2003003385 | A | 20030930 | NO 2003-3385 | 20030729 |
| | US 2004082607 | A1 | 20040429 | US 2003-470805 | 20030801 |
| PRAI | JP 2001-27349 | A | 20010202 | | |
| | JP 2001-292388 | A | 20010925 | | |
| | JP 2001-382232 | A | 20011214 | | |
| | WO 2002-JP831 | W | 20020201 | | |

OS MARPAT 137:169431

IT **447414-07-5P**, 3-(Aminomethyl)-7-benzyloxy-4-butoxy-2-neopentyl-1(2H)-isoquinolinone hydrochloride **447418-39-5P**, 3-(Aminomethyl)-7-(benzyloxy)-2-isobutyl-4-phenyl-1(2H)-isoquinolinone hydrochloride
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of isoquinolinones as dipeptidyl peptidase IV inhibitors for the treatment of diabetes)

RN 447414-07-5 CAPLUS

CN 1(2H)-Isoquinolinone, 3-(aminomethyl)-4-butoxy-2-(2,2-dimethylpropyl)-7-(phenylmethoxy)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 447418-39-5 CAPLUS

CN 1(2H)-Isoquinolinone, 3-(aminomethyl)-2-(2-methylpropyl)-4-phenyl-7-(phenylmethoxy)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

IT **447422-29-9P**, Ethyl 7-benzyloxy-4-hydroxy-2-neopentyl-1-oxo-1,2-

dihydro-3-isoquinolinecarboxylate **447422-30-2P**, Ethyl 7-benzyloxy-4-butoxy-2-neopentyl-1-oxo-1,2-dihydro-3-isoquinolinecarboxylate **447423-78-1P**, Methyl 7-benzyloxy-4-hydroxy-2-isobutyl-1-oxo-1,2-dihydro-3-isoquinolinecarboxylate **447424-10-4P**, tert-Butyl 7-benzyloxy-4-hydroxy-2-isobutyl-1-oxo-1,2-dihydro-3-isoquinolinecarboxylate **447424-26-2P**, Ethyl 7-benzyloxy-4-hydroxy-2-isobutyl-1-oxo-1,2-dihydro-3-isoquinolinecarboxylate **447425-61-8P**, Ethyl 7-(benzyloxy)-2-isobutyl-1-oxo-4-trifluoromethanesulfonyloxy-1,2-dihydro-3-isoquinolinecarboxylate **447425-62-9P**, Ethyl 7-(benzyloxy)-2-isobutyl-1-oxo-4-phenyl-1,2-dihydro-3-isoquinolinecarboxylate **447425-63-0P**, 7-(Benzyloxy)-2-isobutyl-1-oxo-4-phenyl-1,2-dihydro-3-isoquinolinecarboxylic acid **447425-64-1P**, 7-(Benzyloxy)-3-(hydroxymethyl)-2-isobutyl-4-phenyl-1(2H)-isoquinolinone **447425-65-2P**, 7-(Benzyloxy)-3-(chloromethyl)-2-isobutyl-4-phenyl-1(2H)-isoquinolinone **447425-66-3P**, 2-[[7-(Benzyloxy)-2-isobutyl-1-oxo-4-phenyl-1,2-dihydro-3-isoquinolinyl]methyl]-1H-isoindole-1,3(2H)-dione **447425-67-4P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of isoquinolinones as dipeptidyl peptidase IV inhibitors for the treatment of diabetes)

RN 447422-29-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(2,2-dimethylpropyl)-1,2-dihydro-4-hydroxy-1-oxo-7-(phenylmethoxy)-, ethyl ester (9CI) (CA INDEX NAME)




RN 447422-30-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-butoxy-2-(2,2-dimethylpropyl)-1,2-dihydro-1-oxo-7-(phenylmethoxy)-, ethyl ester (9CI) (CA INDEX NAME)




RN 447423-78-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-4-hydroxy-2-(2-methylpropyl)-1-oxo-7-(phenylmethoxy)-, methyl ester (9CI) (CA INDEX NAME)



RN 447424-10-4 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-4-hydroxy-2-(2-methylpropyl)-1-oxo-7-(phenylmethoxy)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 447424-26-2 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-4-hydroxy-2-(2-methylpropyl)-1-oxo-7-(phenylmethoxy)-, ethyl ester (9CI) (CA INDEX NAME)



RN 447425-61-8 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(2-methylpropyl)-1-oxo-7-(phenylmethoxy)-4-[[(trifluoromethyl)sulfonyl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 447425-62-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(2-methylpropyl)-1-oxo-4-phenyl-7-(phenylmethoxy)-, ethyl ester (9CI) (CA INDEX NAME)




RN 447425-63-0 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(2-methylpropyl)-1-oxo-4-phenyl-7-(phenylmethoxy)- (9CI) (CA INDEX NAME)




RN 447425-64-1 CAPLUS
CN 1(2H)-Isoquinolinone, 3-(hydroxymethyl)-2-(2-methylpropyl)-4-phenyl-7-(phenylmethoxy)- (9CI) (CA INDEX NAME)




RN 447425-65-2 CAPLUS
CN 1(2H)-Isoquinolinone, 3-(chloromethyl)-2-(2-methylpropyl)-4-phenyl-7-(phenylmethoxy)- (9CI) (CA INDEX NAME)




RN 447425-66-3 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[[1,2-dihydro-2-(2-methylpropyl)-1-oxo-4-

phenyl-7-(phenylmethoxy)-3-isoquinolinyl]methyl]- (9CI) (CA INDEX NAME)



RN 447425-67-4 CAPLUS
CN Carbamic acid, [[1,2-dihydro-2-(2-methylpropyl)-1-oxo-4-phenyl-7-(phenylmethoxy)-3-isoquinolinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT **447422-31-3,** 7-Benzyloxy-4-butoxy-2-neopentyl-1-oxo-1,2-dihydro-3-isoquinoline-3-carboxylic acid **447422-32-4,** 7-Benzyloxy-4-butoxy-3-hydroxymethyl-2-neopentyl-1(2H)-isoquinolinone **447422-33-5,** 7-Benzyloxy-4-butoxy-3-chloromethyl-2-neopentyl-1(2H)-isoquinolinone **447422-34-6 447422-35-7**
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation of isoquinolinones as dipeptidyl peptidase IV inhibitors for the treatment of diabetes)

RN 447422-31-3 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 4-butoxy-2-(2,2-dimethylpropyl)-1,2-dihydro-1-oxo-7-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 447422-32-4 CAPLUS
CN 1(2H)-Isoquinolinone, 4-butoxy-2-(2,2-dimethylpropyl)-3-(hydroxymethyl)-7-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 447422-33-5 CAPLUS
CN 1(2H)-Isoquinolinone, 4-butoxy-3-(chloromethyl)-2-(2,2-dimethylpropyl)-7-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 447422-34-6 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[[4-butoxy-2-(2,2-dimethylpropyl)-1,2-dihydro-1-oxo-7-(phenylmethoxy)-3-isoquinolinyl]methyl]- (9CI) (CA INDEX NAME)



RN 447422-35-7 CAPLUS
CN Carbamic acid, [[4-butoxy-2-(2,2-dimethylpropyl)-1,2-dihydro-1-oxo-7-(phenylmethoxy)-3-isoquinolinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2001:347100 CAPLUS
DN 134:353303
TI preparation of thiazolidinyl-containing bicyclic heterocycles as humane peroxisome proliferator-activated receptor γ agonists
IN Nomura, Masahiro; Murakami, Koji; Kakuta, Masaki
PA Kyorin Pharmaceutical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | JP 2001131173 | A2 | 20010515 | JP 2000-242708 | 20000810 |
| PRAI | JP 1999-235531 | A | 19990823 | | |

OS MARPAT 134:353303
IT **339152-92-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); IMF (Industrial manufacture); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of bicyclic heterocycles as humane peroxisome proliferator-activated receptor γ agonists)
RN 339152-92-0 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[1,2-dihydro-1-oxo-2-[[4-(trifluoromethyl)phenyl]methyl]-7-isoquinolinyl]methyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2000:151479 CAPLUS
DN 132:194298
TI 4-Phenylisoquinolinone derivatives as cGMP phosphodiesterase inhibitors
IN Ukita, Shinzou; Ohmori, Kenji; Ikeo, Tomihiro
PA Tanabe Seiyaku Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 54 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | JP 2000072751 | A2 | 20000307 | JP 1998-240837 | 19980826 |
| PRAI | JP 1998-240837 | | 19980826 | | |

OS MARPAT 132:194298
IT **260262-98-4P 260263-12-5P 260263-67-0P 260263-78-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of phenylisoquinolinones as cGMP phosphodiesterase inhibitors)

RN 260262-98-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(3-hydroxypropyl)-1-oxo-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 260263-12-5 CAPLUS

CN 2(1H)-Isoquinolinepropanoic acid, 3-(methoxycarbonyl)-1-oxo-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 260263-67-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(3-hydroxypropyl)-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 260263-78-3 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-7-[[6-(hydroxymethyl)-2-pyridinyl]methoxy]-2-(3-hydroxypropyl)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (9CI) (CA INDEX NAME)




IT **260262-99-5P 260263-00-1P 260263-04-5P**
**260263-10-3P 260263-14-7P 260263-18-1P**
**260263-20-5P 260263-23-8P 260263-31-8P**
**260263-32-9P 260263-68-1P 260263-70-5P**
**260263-72-7P 260263-73-8P 260263-74-9P**
**260263-77-2P 260263-79-4P 260263-80-7P**
**260263-81-8P 260263-82-9P 260263-84-1P**
**260263-85-2P 260263-87-4P 260263-88-5P**
**260263-90-9P 260263-93-2P 260263-94-3P**
**260263-95-4P 260263-96-5P 260263-97-6P**
**260264-00-4P 260264-01-5P 260264-02-6P**
**260264-24-2P 260264-25-3P 260264-30-0P**
**260264-31-1P 260264-32-2P 260264-33-3P**
**260264-34-4P 260264-60-6P 260264-61-7P**
**260264-62-8P 260264-63-9P 260264-64-0P**
**260264-65-1P 260264-66-2P 260264-67-3P**
**260264-68-4P 260264-69-5P 260264-70-8P**
**260264-71-9P 260264-73-1P 260264-77-5P**
**260264-78-6P 260264-79-7P 260264-80-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phenylisoquinolinones as cGMP phosphodiesterase inhibitors)

RN 260262-99-5 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-7-(phenylmethoxy)-2-(4-pyridinylmethyl)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 260263-00-1 CAPLUS
CN 2(1H)-Isoquinolinepropanoic acid, 3-(methoxycarbonyl)-1-oxo-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 260263-04-5 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(2-methoxyethyl)-1-oxo-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 260263-10-3 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-7-(phenylmethoxy)-2-(3-pyridinylmethyl)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 260263-14-7 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 4-(4-chloro-3,5-dimethoxyphenyl)-1,2-dihydro-2-(3-hydroxypropyl)-1-oxo-7-(phenylmethoxy)-, methyl ester (9CI) (CA INDEX NAME)



RN 260263-18-1 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-1-oxo-7-(phenylmethoxy)-2-(4-pyridinylmethyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 260263-20-5 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-1-oxo-7-(phenylmethoxy)-2-(3-pyridinylmethyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 260263-23-8 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 4-(4-chloro-3,5-dimethoxyphenyl)-1,2-dihydro-1-oxo-7-(phenylmethoxy)-2-(4-pyridinylmethyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 260263-31-8 CAPLUS
CN 2(1H)-Isoquinolinepropanoic acid, 3-(methoxycarbonyl)-1-oxo-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 260263-32-9 CAPLUS
CN 2(1H)-Isoquinolinepropanoic acid, 3-(methoxycarbonyl)-1-oxo-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)



RN 260263-68-1 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(3-hydroxypropyl)-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 260263-70-5 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(2-methoxyethyl)-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 260263-72-7 CAPLUS
CN 2(1H)-Isoquinolinepropanoic acid, 3-(methoxycarbonyl)-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 260263-73-8 CAPLUS
CN 2(1H)-Isoquinolinepropanoic acid, 7-[(3-carboxyphenyl)methoxy]-3-(methoxycarbonyl)-1-oxo-4-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)



RN 260263-74-9 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-2-(3-hydroxypropyl)-1-oxo-7-(2-pyridinylmethoxy)-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 260263-77-2 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 4-(4-chloro-3,5-dimethoxyphenyl)-1,2-dihydro-2-(3-hydroxypropyl)-1-oxo-7-(2-pyridinylmethoxy)-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 260263-79-4 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-7-[[6-(hydroxymethyl)-2-pyridinyl]methoxy]-2-(3-hydroxypropyl)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 260263-80-7 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-2-(4-pyridinylmethyl)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 260263-81-8 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-7-[[6-(hydroxymethyl)-2-pyridinyl]methoxy]-1-oxo-2-(4-pyridinylmethyl)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 260263-82-9 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-2-(4-pyridinylmethyl)-7-(2-pyrimidinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 260263-84-1 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-7-[[6-(hydroxymethyl)-2-pyridinyl]methoxy]-2-(2-methoxyethyl)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 260263-85-2 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(2-methoxyethyl)-1-oxo-7-(pyrazinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 260263-87-4 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-7-[[6-(hydroxymethyl)-2-pyridinyl]methoxy]-1-oxo-2-(3-pyridinylmethyl)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 260263-88-5 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-2-(3-pyridinylmethyl)-7-(2-pyrimidinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 260263-90-9 CAPLUS
CN 2(1H)-Isoquinolinepropanoic acid, 7-[[6-(hydroxymethyl)-2-pyridinyl]methoxy]-3-(methoxycarbonyl)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 260263-93-2 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-2-(4-pyridinylmethyl)-, methyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 260263-94-3 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-7-[[6-(hydroxymethyl)-2-pyridinyl]methoxy]-1-oxo-2-(4-pyridinylmethyl)-, methyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 260263-95-4 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-7-[[6-(hydroxymethyl)-2-pyridinyl]methoxy]-2-(3-hydroxypropyl)-1-oxo-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 260263-96-5 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-2-(3-pyridinylmethyl)-, methyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 260263-97-6 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-7-[[6-(hydroxymethyl)-2-pyridinyl]methoxy]-1-oxo-2-(3-pyridinylmethyl)-, methyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 260264-00-4 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 4-(4-chloro-3,5-dimethoxyphenyl)-1,2-dihydro-7-[[6-(hydroxymethyl)-2-pyridinyl]methoxy]-1-oxo-2-(4-pyridinylmethyl)-, methyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 260264-01-5 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 4-(4-chloro-3,5-dimethoxyphenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-2-(4-pyridinylmethyl)-, methyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 260264-02-6 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 4-(4-chloro-3,5-dimethoxyphenyl)-1,2-dihydro-7-[[6-(hydroxymethyl)-2-pyridinyl]methoxy]-2-(3-hydroxypropyl)-1-oxo-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 260264-24-2 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-methyl-1-oxo-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 260264-25-3 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 2-ethyl-1,2-dihydro-1-oxo-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 260264-30-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-7-(phenylmethoxy)-2-(2-pyridinylmethyl)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 260264-31-1 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-[(2-methyl-3-pyridinyl)methyl]-1-oxo-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 260264-32-2 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-[(6-methyl-3-pyridinyl)methyl]-1-oxo-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 260264-33-3 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-[(2-methyl-4-

pyridinyl)methyl]-1-oxo-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 260264-34-4 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 2-(3-amino-3-oxopropyl)-1,2-dihydro-1-oxo-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 260264-60-6 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-[(2-methyl-3-pyridinyl)methyl]-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 260264-61-7 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-[(6-methyl-3-pyridinyl)methyl]-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 260264-62-8 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-2-(2-pyridinylmethyl)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 260264-63-9 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-7-[[6-(hydroxymethyl)-2-pyridinyl]methoxy]-1-oxo-2-(2-pyridinylmethyl)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 260264-64-0 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-[(2-methyl-3-pyridinyl)methyl]-1-oxo-7-(2-pyrimidinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 260264-65-1 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-[(2-methyl-3-pyridinyl)methyl]-1-oxo-7-(pyrazinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 260264-66-2 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-[(6-methyl-3-pyridinyl)methyl]-1-oxo-7-(2-pyrimidinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 260264-67-3 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-[(6-methyl-3-pyridinyl)methyl]-1-oxo-7-(pyrazinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 260264-68-4 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-[(2-methyl-4-pyridinyl)methyl]-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 260264-69-5 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-[(2-methyl-4-pyridinyl)methyl]-1-oxo-7-(2-pyrimidinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 260264-70-8 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-[(2-methyl-4-pyridinyl)methyl]-1-oxo-7-(pyrazinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 260264-71-9 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 2-(3-amino-3-oxopropyl)-1,2-dihydro-1-oxo-7-

(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 260264-73-1 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(3-hydroxypropyl)-1-oxo-7-(2-pyrimidinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 260264-77-5 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-methyl-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 260264-78-6 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-methyl-1-oxo-7-(2-pyrimidinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 260264-79-7 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 2-ethyl-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 260264-80-0 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 2-ethyl-1,2-dihydro-1-oxo-7-(2-pyrimidinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (9CI) (CA INDEX NAME)



IT **260262-97-3P 260263-03-4P 260263-09-0P 260263-11-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of phenylisoquinolinones as cGMP phosphodiesterase inhibitors)
RN 260262-97-3 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(3-hydroxypropyl)-1-oxo-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)



RN 260263-03-4 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(2-methoxyethyl)-1-oxo-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)



RN 260263-09-0 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-7-(phenylmethoxy)-2-(3-pyridinylmethyl)-4-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)



RN 260263-11-4 CAPLUS
CN 2(1H)-Isoquinolinepropanoic acid, 3-carboxy-1-oxo-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, α-(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1999:206731 CAPLUS
DN 131:88069
TI Total syntheses of (±)-cherylline and (±)-latifine
AU Couture, Axel; Deniau, Eric; Lebrun, Stephane; Grandclaudon, Pierre
CS Associe au CNRS (UPRESA 8009), Laboratoire de Chimie Organique Physique, Universite des Sciences et Technologies de Lille 1, Villeneuve d'Ascq, F-59655, Fr.
SO Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1999), (7), 789-794
CODEN: JCPRB4; ISSN: 0300-922X
PB Royal Society of Chemistry
DT Journal
LA English
OS CASREACT 131:88069
IT **229017-32-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(total syntheses of (±)-cherylline and (±)-latifine)
RN 229017-32-7 CAPLUS
CN 1(2H)-Isoquinolinone, 6-methoxy-2-methyl-7-(phenylmethoxy)-4-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1994:106793 CAPLUS
DN 120:106793
TI Preparation and formulation of N-(pyridylmethyl)isoindole(di)ones and

-isoquinolinones and analogs as PAF antagonists
IN Yamamoto, Akihiro; Morita, Shuji; Hayashi, Yoshio; Yamada, Noboru; Kitamura, Toshihito
PA Mitsubishi Kasei Corp., Japan
SO Eur. Pat. Appl., 49 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | EP 548934 | A1 | 19930630 | EP 1992-121832 | 19921222 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE | | | | |
| | US 5304556 | A | 19940419 | US 1992-993044 | 19921218 |
| | JP 06220044 | A2 | 19940809 | JP 1992-338958 | 19921218 |
| | CA 2085963 | AA | 19930626 | CA 1992-2085963 | 19921221 |
| | US 5401756 | A | 19950328 | US 1994-190609 | 19940202 |
| PRAI | JP 1991-343687 | A | 19911225 | | |
| | JP 1992-305574 | A | 19921116 | | |
| | US 1992-993044 | A3 | 19921218 | | |

OS MARPAT 120:106793
IT **152265-36-6P 152265-37-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as PAF antagonist)
RN 152265-36-6 CAPLUS
CN 1(2H)-Isoquinolinone, 7-(4-chlorophenoxy)-2-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 152265-37-7 CAPLUS
CN 1(2H)-Isoquinolinone, 7-(4-methylphenoxy)-2-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1993:22155 CAPLUS
DN 118:22155
TI Preparation of substituted 1(2H)-isoquinolinones as angiotensin II antagonists
IN Patchett, Arthur A.; De Laszlo, Stephen E.; Greenlee, William J.
PA Merck and Co., Inc., USA
SO Eur. Pat. Appl., 68 pp.
CODEN: EPXXDW
DT Patent

LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | EP 502575 | A1 | 19920909 | EP 1992-200563 | 19920227 |
| | R: CH, DE, FR, GB, IT, LI, NL | | | | |
| | CA 2062211 | AA | 19920907 | CA 1992-2062211 | 19920303 |
| | JP 05148238 | A2 | 19930615 | JP 1992-98999 | 19920306 |
| | JP 07035372 | B4 | 19950419 | | |
| PRAI | US 1991-665491 | A | 19910306 | | |
| | US 1992-830621 | A | 19920211 | | |

OS MARPAT 118:22155
IT **144871-26-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as angiotensin II antagonist)
RN 144871-26-1 CAPLUS
CN Carbamic acid, [1,2-dihydro-1-oxo-3-propyl-2-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-7-isoquinolinyl](phenylmethyl)-, 2-methylpropyl ester (9CI) (CA INDEX NAME)




L4 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1988:56398 CAPLUS
DN 108:56398
TI A new total synthesis of oxyterihanine
AU Hanaoka, Miyoji; Kobayashi, Nobuyuki; Mukai, Chisato
CS Fac. Pharm. Sci., Kanazawa Univ., Kanazawa, 920, Japan
SO Heterocycles (1987), 26(6), 1499-501
CODEN: HTCYAM; ISSN: 0385-5414
DT Journal
LA English
OS CASREACT 108:56398
IT **112448-31-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and intramol. cyclization of, oxyterihanine derivative from)
RN 112448-31-4 CAPLUS
CN 1(2H)-Isoquinolinone, 3-[6-(2,2-dimethoxyethyl)-1,3-benzodioxol-5-yl]-6-methoxy-2-methyl-7-(phenylmethoxy)- (9CI) (CA INDEX NAME)



IT **112448-30-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and methoxylation of)
RN 112448-30-3 CAPLUS
CN 1(2H)-Isoquinolinone, 3-(6-ethenyl-1,3-benzodioxol-5-yl)-6-methoxy-2-methyl-7-(phenylmethoxy)- (9CI) (CA INDEX NAME)



=> log y

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 30.96 | 192.93 |

STN INTERNATIONAL LOGOFF AT 14:16:12 ON 15 OCT 2005

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1611bxv

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

| | | | |
|---|---|---|---|
| NEWS | 1 | | Web Page URLs for STN Seminar Schedule - N. America |
| NEWS | 2 | | "Ask CAS" for self-help around the clock |
| NEWS | 3 | JUL 20 | Powerful new interactive analysis and visualization software, STN AnaVist, now available |
| NEWS | 4 | AUG 11 | STN AnaVist workshops to be held in North America |
| NEWS | 5 | AUG 30 | CA/CAplus -Increased access to 19th century research documents |
| NEWS | 6 | AUG 30 | CASREACT - Enhanced with displayable reaction conditions |
| NEWS | 7 | SEP 09 | ACD predicted properties enhanced in REGISTRY/ZREGISTRY |
| NEWS | 8 | OCT 03 | MATHDI removed from STN |
| NEWS | 9 | OCT 04 | CA/CAplus-Canadian Intellectual Property Office (CIPO) added to core patent offices |
| NEWS | 10 | OCT 06 | STN AnaVist workshops to be held in North America |
| NEWS | 11 | OCT 13 | New CAS Information Use Policies Effective October 17, 2005 |

| | |
|---|---|
| NEWS EXPRESS | JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005 |
| NEWS HOURS | STN Operating Hours Plus Help Desk Availability |
| NEWS INTER | General Internet Information |
| NEWS LOGIN | Welcome Banner and News Items |
| NEWS PHONE | Direct Dial and Telecommunication Network Access to STN |
| NEWS WWW | CAS World Wide Web Site (general information) |

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:02:56 ON 15 OCT 2005

=> file reg

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 0.21 | 0.21 |

FILE 'REGISTRY' ENTERED AT 14:03:04 ON 15 OCT 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 14 OCT 2005 HIGHEST RN 865347-39-3
DICTIONARY FILE UPDATES: 14 OCT 2005 HIGHEST RN 865347-39-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

**********
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
**********

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Documents and Settings\VBalasubramania\My Documents\STNEXP4\QUERIES\10634473.str




chain nodes :
11 13 14
ring nodes :
1 2 3 4 5 6 7 8 9 10
chain bonds :
3-11 11-13 13-14
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10
exact/norm bonds :
3-11 5-7 6-10 7-8 8-9 9-10 11-13 13-14
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

G1:C,O,S,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 13:CLASS 14:Atom

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR




G1 C,O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam
SAMPLE SEARCH INITIATED 14:03:26 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 30978 TO ITERATE

6.5% PROCESSED 2000 ITERATIONS 32 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 609039 TO 630081
PROJECTED ANSWERS: 8577 TO 11247

L2 32 SEA SSS SAM L1

=> d scan

L2 32 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, N-[2-[[4-[[(2-amino-2-oxoethyl)propylamino]carbonyl]phenyl]methyl]-1,2,3,4-tetrahydro-3-(1H-imidazol-2-yl)-1-oxo-7-isoquinolinyl]-3-(trifluoromethyl)- (9CI)
MF C34 H33 F3 N6 O4



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):31

L2 32 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Isoquinoline, 1,2,3,4-tetrahydro-6-methoxy-7-(phenylmethoxy)-1-[[4-(phenylmethoxy)phenyl]methyl]-, hydrochloride (9CI)
MF C31 H31 N O3 . Cl H



● HCl

L2 32 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzoic acid, 4-[[3,4-dihydro-1-oxo-3-(2-quinolinyl)-7-[(2,3,5,6-tetrafluoro-4-methylbenzoyl)amino]-2(1H)-isoquinolinyl]methyl]-, 2-amino-2-oxoethyl ester (9CI)
MF C36 H26 F4 N4 O5



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 32 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2-Thiophenepropanoic acid, α-[[[1-(cyclopentylmethyl)-7-[[trans-4-(1,1-dimethylethyl)cyclohexyl]oxy]-3-isoquinolinyl]carbonyl]amino]-5-(1-methylethenyl)-, (αS)- (9CI)
MF C36 H46 N2 O4 S

Absolute stereochemistry.



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 32 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzamide, N-(2-amino-2-oxoethyl)-4-[[7-[(2-bromobenzoyl)amino]-3,4-dihydro-1-oxo-3-(3-pyridinyl)-2(1H)-isoquinolinyl]methyl]-N-(3-pyridinylmethyl)- (9CI)
MF C37 H31 Br N6 O4



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 32 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 3-Isoquinolinecarboxamide, N-(2-[1,1'-biphenyl]-4-ylethyl)-1-(cyclopentylmethyl)-7-[4-(1,1-dimethylethyl)phenoxy]- (9CI)
MF C40 H42 N2 O2




**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 32 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzamide, N-(2-amino-2-oxoethyl)-N-[3-(diethylamino)propyl]-4-[[7-[(3,4-difluorobenzoyl)amino]-3,4-dihydro-1-oxo-3-(2-pyridinyl)-2(1H)-isoquinolinyl]methyl]- (9CI)
MF C38 H40 F2 N6 O4




**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 32 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Isoquinoline, 1,2,3,4-tetrahydro-5,7-bis(phenylmethoxy)-1-[1-(3,4,5-trimethoxyphenyl)ethyl]-, (R*,R*)- (9CI)
MF C34 H37 N O5
CI COM

Relative stereochemistry.




**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 32 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzamide, N-(2-amino-2-oxoethyl)-4-[[7-[(3,4-difluorobenzoyl)amino]-3,4-dihydro-3-(4-methylphenyl)-1-oxo-2(1H)-isoquinolinyl]methyl]-N-2-propenyl- (9CI)
MF C36 H32 F2 N4 O4




**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 32 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Isoquinoline, 1,2,3,4-tetrahydro-6-methoxy-7-[[4-[[4-(trifluoromethyl)phenyl]methoxy]phenyl]sulfonyl]- (9CI)
MF C24 H22 F3 N O4 S



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 32 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzamide, N-(2-amino-2-oxoethyl)-4-[[7-[(cyclopentylacetyl)amino]-3-(3,4-difluorophenyl)-3,4-dihydro-1-oxo-2(1H)-isoquinolinyl]methyl]-N-cyclopropyl- (9CI)
MF C35 H36 F2 N4 O4



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 32 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 3-Isoquinolinecarboxylic acid, 2-(2,2-dimethylpropyl)-1,2,3,4-tetrahydro-7-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-, calcium salt, (3S)- (9CI)
MF C27 H32 N2 O4 . 1/2 Ca

Absolute stereochemistry.



●1/2 Ca

L2 32 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Isoquinolinepropanamide, N-(2-amino-2-oxoethyl)-7-[[2-fluoro-3-(trifluoromethyl)benzoyl]amino]-3,4-dihydro-3-(1H-imidazol-2-yl)-1-oxo-N-[[3-(trifluoromethyl)phenyl]methyl]- (9CI)
MF C33 H27 F7 N6 O4

PAGE 1-A



PAGE 1-B

—CF3

**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 32 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Bicyclo[2.2.1]heptane-2-acetamide, N-[2-[[4-[[(2-amino-2-oxoethyl)(phenylmethyl)amino]carbonyl]phenyl]methyl]-3-[4-[3-(dimethylamino)propoxy]phenyl]-1,2,3,4-tetrahydro-1-oxo-7-isoquinolinyl]-, (1S,2R,4R)- (9CI)
MF C46 H53 N5 O5

Absolute stereochemistry.



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 32 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Isoquinolinecarboxamidamide, 3,4-dihydro-7-[[1-(4-quinolinyl)-4-piperidinyl]methoxy]-, dihydrochloride (9CI)
MF C25 H29 N5 O . 2 Cl H



●2 HCl

L2 32 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Isoquinolinepropanamide, N-(2-amino-2-oxoethyl)-7-[(2-fluorobenzoyl)amino]-3,4-dihydro-1-oxo-3-(2-pyridinyl)-N-[2-(2-pyridinyl)ethyl]- (9CI)
MF C33 H31 F N6 O4



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 32 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Pentanoic acid, 4-[[1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-isoquinolinyl]methyl]-2-[[1,2,3,4-tetrahydro-6-methoxy-1-[(4-methoxyphenyl)methyl]-2-methyl-7-isoquinolinyl]oxy]phenyl ester, [R-(R*,R*)]- (9CI)
MF C43 H52 N2 O7

Absolute stereochemistry.



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 32 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Isoquinolinepropanamide, N-(2-amino-2-oxoethyl)-7-[[(2-chloro-3-pyridinyl)carbonyl]amino]-N-[3-(diethylamino)propyl]-3-(3,4-difluorophenyl)-3,4-dihydro-1-oxo- (9CI)
MF C33 H37 Cl F2 N6 O4



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 32 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Butanedioic acid, 2,3-bis(benzoyloxy)-, [S-(R*,R*)]-, compd. with (S)-1,2,3,4-tetrahydro-6-methoxy-1-[[4-methoxy-3-(phenylmethoxy)phenyl]methyl]-7-(phenylmethoxy)isoquinoline (1:1) (9CI)
MF C32 H33 N O4 . C18 H14 O8

CM 1

Absolute stereochemistry.



CM 2

Absolute stereochemistry. Rotation (+).



L2 32 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzoic acid, 4-[[7-[[2-fluoro-3-(trifluoromethyl)benzoyl]amino]-3,4-dihydro-1-oxo-3-(2-quinolinyl)-2(1H)-isoquinolinyl]methyl]-, 2-amino-2-oxoethyl ester (9CI)
MF C36 H26 F4 N4 O5



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 32 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Isoquinolinium, 7-(benzyloxy)-1,2,3,4-tetrahydro-6-methoxy-2,2-dimethyl-1-veratryl-, iodide (5CI)
MF C28 H34 N O4 . I





L2 32 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzamide, N-(2-amino-2-oxoethyl)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-4-[[7-[(2-fluorobenzoyl)amino]-3,4-dihydro-1-oxo-3-phenyl-2(1H)-isoquinolinyl]methyl]- (9CI)
MF C39 H40 F N5 O4



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 32 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN L-Alanine, N-[(4-mercapto-7-phenoxy-3-isoquinolinyl)carbonyl]- (9CI)
MF C19 H16 N2 O4 S

Absolute stereochemistry.



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 32 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzamide, N-(2-amino-2-oxoethyl)-4-[[7-[(2,6-difluorobenzoyl)amino]-3,4-dihydro-3-[4-(methylthio)phenyl]-1-oxo-2(1H)-isoquinolinyl]methyl]-N-(3-ethoxypropyl)- (9CI)
MF C38 H38 F2 N4 O5 S



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 32 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN

IN Isoquinoline, 7-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(hexahydro-1H-1,4-diazepin-1-yl)-, monohydrochloride (9CI)
MF C24 H29 N3 O2 S . Cl H




● HCl

L2 32 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2-Furancarboxamide, N-[2-[[4-[[(2-amino-2-oxoethyl)propylamino]carbonyl]phenyl]methyl]-1,2,3,4-tetrahydro-3-[4-(methylthio)phenyl]-1-oxo-7-isoquinolinyl]tetrahydro- (9CI)
MF C34 H38 N4 O5 S




**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 32 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzo[b]thiophene-2-sulfonamide, N-[(3R)-1-[(1-amino-7-isoquinolinyl)methyl]-2-oxo-3-pyrrolidinyl]-, mono(trifluoroacetate) (9CI)
MF C22 H20 N4 O3 S2 . C2 H F3 O2

CM 1

Absolute stereochemistry.



CM 2



L2 32 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Isoquinolinepropanamide, N-(2-amino-2-oxoethyl)-7-[(2-furanylcarbonyl)amino]-3,4-dihydro-1-oxo-3-phenyl-N-propyl- (9CI)
MF C28 H30 N4 O5



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 32 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Isoquinoline, 7-[2-[4-(3-fluorophenyl)-3,6-dihydro-1(2H)-pyridinyl]ethyl]-, dihydrochloride (9CI)
MF C22 H21 F N2 . 2 Cl H



●2 HCl

L2 32 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN

IN 3-Isoquinolinecarboxylic acid, 2-[(2E)-3-(2-bromophenyl)-1-oxo-2-propenyl]-7-[(2,4-dichlorophenyl)methoxy]-1,2,3,4-tetrahydro-6,8-diiodo-, (3S)- (9CI)
MF C26 H18 Br Cl2 I2 N O4

Absolute stereochemistry.
Double bond geometry as shown.




**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 32 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzamide, N-(2-amino-2-oxoethyl)-4-[[7-[(2-bromo-5-methoxybenzoyl)amino]-3-(3,4-difluorophenyl)-3,4-dihydro-1-oxo-2(1H)-isoquinolinyl]methyl]-N-[(3-pyridinyl)methyl]- (9CI)
MF C39 H32 Br F2 N5 O5




**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 32 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1H-Pyrrole-2-carboxamide, N-(aminoiminomethyl)-3-(7-isoquinolinyloxy)-1-methyl-4-(methylsulfonyl)- (9CI)
MF C17 H17 N5 O4 S



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

ALL ANSWERS HAVE BEEN SCANNED

=> log y

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 0.86 | 1.07 |

STN INTERNATIONAL LOGOFF AT 14:04:03 ON 15 OCT 2005

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1611bxv

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

| | | | |
|---|---|---|---|
| NEWS | 1 | | Web Page URLs for STN Seminar Schedule - N. America |
| NEWS | 2 | | "Ask CAS" for self-help around the clock |
| NEWS | 3 | JUL 20 | Powerful new interactive analysis and visualization software, STN AnaVist, now available |
| NEWS | 4 | AUG 11 | STN AnaVist workshops to be held in North America |
| NEWS | 5 | AUG 30 | CA/CAplus -Increased access to 19th century research documents |
| NEWS | 6 | AUG 30 | CASREACT - Enhanced with displayable reaction conditions |
| NEWS | 7 | SEP 09 | ACD predicted properties enhanced in REGISTRY/ZREGISTRY |
| NEWS | 8 | OCT 03 | MATHDI removed from STN |
| NEWS | 9 | OCT 04 | CA/CAplus-Canadian Intellectual Property Office (CIPO) added to core patent offices |
| NEWS | 10 | OCT 06 | STN AnaVist workshops to be held in North America |
| NEWS | 11 | OCT 13 | New CAS Information Use Policies Effective October 17, 2005 |

| | |
|---|---|
| NEWS EXPRESS | JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005 |
| NEWS HOURS | STN Operating Hours Plus Help Desk Availability |
| NEWS INTER | General Internet Information |
| NEWS LOGIN | Welcome Banner and News Items |
| NEWS PHONE | Direct Dial and Telecommunication Network Access to STN |
| NEWS WWW | CAS World Wide Web Site (general information) |

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:05:35 ON 15 OCT 2005

=> file reg

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 0.21 | 0.21 |

FILE 'REGISTRY' ENTERED AT 14:05:44 ON 15 OCT 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 14 OCT 2005 HIGHEST RN 865347-39-3
DICTIONARY FILE UPDATES: 14 OCT 2005 HIGHEST RN 865347-39-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

**********
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
**********

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Documents and Settings\VBalasubramania\My Documents\STNEXP4\QUERIES\10634473-2.str




chain nodes :
11 13 14 18
ring nodes :
1 2 3 4 5 6 7 8 9 10
chain bonds :
3-11 7-18 11-13 13-14
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10
exact/norm bonds :
3-11 5-7 6-10 7-8 7-18 8-9 9-10 11-13 13-14
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :
containing 1 :

G1:C,O,S,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 13:CLASS 14:Atom 18:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR




G1 C,O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam
SAMPLE SEARCH INITIATED 14:06:05 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 6742 TO ITERATE

29.7% PROCESSED 2000 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 129918 TO 139762
PROJECTED ANSWERS: 4715 TO 6745

L2 50 SEA SSS SAM L1

=> d scan

L2 50 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzamide, N-(2-amino-2-oxoethyl)-4-[[3-(3,4-difluorophenyl)-3,4-dihydro-1-oxo-7-[[4-(trifluoromethoxy)benzoyl]amino]-2(1H)-isoquinolinyl]methyl]-N-[2-(2-pyridinyl)ethyl]- (9CI)
MF C40 H32 F5 N5 O5

PAGE 1-A



PAGE 1-B



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):49

L2 50 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Bicyclo[2.2.1]heptane-2-acetamide, N-[2-[[4-[[(2-amino-2-oxoethyl)(phenylmethyl)amino]carbonyl]phenyl]methyl]-3-[4-[3-(dimethylamino)propoxy]phenyl]-1,2,3,4-tetrahydro-1-oxo-7-isoquinolinyl]-, (1S,2R,4R)- (9CI)
MF C46 H53 N5 O5

Absolute stereochemistry.



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 50 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Isoquinolinepropanamide, N-(2-amino-2-oxoethyl)-7-[(4-cyanobenzoyl)amino]-3-(3,4-difluorophenyl)-3,4-dihydro-1-oxo-N-(3-pyridinylmethyl)- (9CI)
MF C34 H28 F2 N6 O4



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 50 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2-Furancarboxamide, N-[2-[[4-[[(2-amino-2-oxoethyl)propylamino]carbonyl]phenyl]methyl]-1,2,3,4-tetrahydro-3-(4-methylphenyl)-1-oxo-7-isoquinolinyl]- (9CI)
MF C34 H34 N4 O5



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 50 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Isoquinolinepropanamide, N-(2-amino-2-oxoethyl)-7-[(cyclopentylacetyl)amino]-3-(3,4-difluorophenyl)-3,4-dihydro-N-[3-(1H-imidazol-1-yl)propyl]-1-oxo- (9CI)
MF C33 H38 F2 N6 O4



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 50 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1-Piperazineacetamide, 4-[3-[3,4-dihydro-3-(1-naphthalenyl)-1-oxo-7-[[(1-phenylcyclopropyl)carbonyl]amino]-2(1H)-isoquinolinyl]-1-oxopropyl]- (9CI)
MF C38 H39 N5 O4



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 50 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, N-[2-[[4-[[(2-amino-2-oxoethyl)cyclopropylamino]carbonyl]phenyl]methyl]-1,2,3,4-tetrahydro-1-oxo-3-(3-pyridinyl)-7-isoquinolinyl]-2,4,6-trimethyl-α-oxo- (9CI)
MF C38 H37 N5 O5





**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 50 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Isoquinolinepropanamide, N-(2-amino-2-oxoethyl)-7-[(2-fluorobenzoyl)amino]-3,4-dihydro-1-oxo-3-(2-pyridinyl)-N-[2-(2-pyridinyl)ethyl]- (9CI)
MF C33 H31 F N6 O4



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 50 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Isoquinolinepropanamide, N-(2-amino-2-oxoethyl)-3-[4-[3-(dimethylamino)propoxy]phenyl]-7-[(2-fluorobenzoyl)amino]-3,4-dihydro-1-oxo-N-propyl- (9CI)
MF C35 H42 F N5 O5



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 50 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1-Piperazineacetamide, 4-[3-[3-(3-cyanophenyl)-7-[(2-fluorobenzoyl)amino]-3,4-dihydro-1-oxo-2(1H)-isoquinolinyl]-1-oxopropyl]- (9CI)
MF C32 H31 F N6 O4



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 50 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzamide, N-(2-amino-2-oxoethyl)-4-[[3-(3-cyanophenyl)-7-[(cyclopentylacetyl)amino]-3,4-dihydro-1-oxo-2(1H)-isoquinolinyl]methyl]-N-(phenylmethyl)- (9CI)
MF C40 H39 N5 O4



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 50 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1-Piperazineacetamide, 4-[4-[[3-[4-(1,1-dimethylethyl)phenyl]-7-[(2-fluorobenzoyl)amino]-3,4-dihydro-1-oxo-2(1H)-isoquinolinyl]methyl]benzoyl]- (9CI)
MF C40 H42 F N5 O4



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 50 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzamide, N-(2-amino-2-oxoethyl)-4-[[7-[(3-cyclohexyl-1-oxopropyl)amino]-3,4-dihydro-1-oxo-3-(2-pyridinyl)-2(1H)-isoquinolinyl]methyl]-N-[(1-ethyl-2-pyrrolidinyl)methyl]- (9CI)
MF C40 H50 N6 O4

PAGE 1-A



PAGE 1-B



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 50 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Isoquinolinepropanamide, N-(2-amino-2-oxoethyl)-N-cyclopropyl-3,4-dihydro-3-(4-methylphenyl)-7-[[2-(methylthio)benzoyl]amino]-1-oxo- (9CI)
MF C32 H34 N4 O4 S



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 50 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzoic acid, 4-[[3,4-dihydro-1-oxo-3-(2-quinolinyl)-7-[(2,3,5,6-tetrafluoro-4-methylbenzoyl)amino]-2(1H)-isoquinolinyl]methyl]-, 2-amino-2-oxoethyl ester (9CI)
MF C36 H26 F4 N4 O5



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 50 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzoic acid, 4-[[7-[[(2-chloro-3-pyridinyl)carbonyl]amino]-3,4-dihydro-1-oxo-3-phenyl-2(1H)-isoquinolinyl]methyl]-, 2-amino-2-oxoethyl ester (9CI)
MF C31 H25 Cl N4 O5



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 50 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Isoquinolinepropanoic acid, 3-(3,4-difluorophenyl)-3,4-dihydro-1-oxo-7-[(2,3,5,6-tetrafluoro-4-methylbenzoyl)amino]-, 2-amino-2-oxoethyl ester (9CI)
MF C28 H21 F6 N3 O5



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 50 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 5-Pyrimidinecarboxamide, 4-[(phenylmethyl)amino]-2-[(1,2,3,4-tetrahydro-2-methyl-1-oxo-7-isoquinolinyl)amino]- (9CI)
MF C22 H22 N6 O2
CI COM



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 50 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, N-[2-[[4-[[(2-amino-2-oxoethyl)[2-(dimethylamino)ethyl]amino]carbonyl]phenyl]methyl]-3-(3,5-dimethoxyphenyl)-1,2,3,4-tetrahydro-1-oxo-7-isoquinolinyl]-3-(trifluoromethyl)- (9CI)
MF C40 H42 F3 N5 O6

PAGE 1-A



PAGE 1-B

**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 50 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN

IN Benzoic acid, 4-[[7-[(3-cyclopentyl-1-oxopropyl)amino]-3,4-dihydro-1-oxo-3-phenyl-2(1H)-isoquinolinyl]methyl]-, 2-amino-2-oxoethyl ester (9CI)
MF C33 H35 N3 O5



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 50 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzamide, N-(2-amino-2-oxoethyl)-4-[[7-[(3-cyclopentyl-1-oxopropyl)amino]-3-(3,5-dimethoxyphenyl)-3,4-dihydro-1-oxo-2(1H)-isoquinolinyl]methyl]-N-cyclopropyl- (9CI)
MF C38 H44 N4 O6



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 50 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzamide, N-(2-amino-2-oxoethyl)-4-[[3-(3,4-difluorophenyl)-7-[(2-fluorobenzoyl)amino]-3,4-dihydro-1-oxo-2(1H)-isoquinolinyl]methyl]-N-(2-methoxyethyl)- (9CI)
MF C35 H31 F3 N4 O5



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 50 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Isoquinolinepropanoic acid, 7-[(4-cyanobenzoyl)amino]-3,4-dihydro-1-oxo-3-(2-pyridinyl)-, 2-amino-2-oxoethyl ester (9CI)
MF C27 H23 N5 O5



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 50 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzamide, N-(2-amino-2-oxoethyl)-4-[[7-[(2-fluorobenzoyl)amino]-3,4-dihydro-1-oxo-3-(3-pyridinyl)-2(1H)-isoquinolinyl]methyl]-N-(phenylmethyl)- (9CI)
MF C38 H32 F N5 O4



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 50 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Isoquinolinepropanamide, N-(2-amino-2-oxoethyl)-N-[3-

(diethylamino)propyl]-7-[[2-fluoro-3-(trifluoromethyl)benzoyl]amino]-3,4-dihydro-1-oxo-3-(3-pyridinyl)- (9CI)
MF C34 H38 F4 N6 O4



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 50 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Isoquinolinepropanoic acid, 3-[4-(acetylamino)phenyl]-7-[(3,4-difluorobenzoyl)amino]-3,4-dihydro-1-oxo-, 2-amino-2-oxoethyl ester (9CI)
MF C29 H26 F2 N4 O6



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 50 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Isoquinolinepropanoic acid, 3,4-dihydro-7-[[(4-methyl-1,2,3-thiadiazol-5-yl)carbonyl]amino]-3-(1-naphthalenyl)-1-oxo-, 2-amino-2-oxoethyl ester (9CI)
MF C28 H25 N5 O5 S



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 50 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Isoquinolinepropanamide, N-(2-amino-2-oxoethyl)-3-(3-cyanophenyl)-7-[[2-fluoro-3-(trifluoromethyl)benzoyl]amino]-3,4-dihydro-1-oxo-N-(3-pyridinylmethyl)- (9CI)
MF C35 H28 F4 N6 O4



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 50 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 3-Pyridinecarboxamide, N-[2-[[4-[[(2-amino-2-oxoethyl)[2-(dimethylamino)ethyl]amino]carbonyl]phenyl]methyl]-1,2,3,4-tetrahydro-3-(4-methylphenyl)-1-oxo-7-isoquinolinyl]-2-chloro- (9CI)
MF C36 H37 Cl N6 O4



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 50 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzamide, N-(2-amino-2-oxoethyl)-N-cyclopropyl-4-[[7-[(2-fluorobenzoyl)amino]-3,4-dihydro-1-oxo-3-phenyl-2(1H)-isoquinolinyl]methyl]- (9CI)
MF C35 H31 F N4 O4



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 50 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2-Furancarboxamide, N-[2-[[4-[[(2-amino-2-oxoethyl)(2-methoxyethyl)amino]carbonyl]phenyl]methyl]-1,2,3,4-tetrahydro-3-[4-(methylthio)phenyl]-1-oxo-7-isoquinolinyl]tetrahydro- (9CI)
MF C34 H38 N4 O6 S



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 50 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2-Furancarboxamide, N-[2-[[4-[[(2-amino-2-oxoethyl)propylamino]carbonyl]phenyl]methyl]-1,2,3,4-tetrahydro-1-oxo-3-[4-(trifluoromethyl)phenyl]-7-isoquinolinyl]- (9CI)
MF C34 H31 F3 N4 O5



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 50 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Isoquinolinepropanoic acid, 3,4-dihydro-1-oxo-3-(2-quinolinyl)-7-[[4-(trifluoromethoxy)benzoyl]amino]-, 2-amino-2-oxoethyl ester (9CI)
MF C31 H25 F3 N4 O6



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 50 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 3-Pyridinecarboxamide, N-[2-[[4-[[(2-amino-2-oxoethyl)[2-(2-pyridinyl)ethyl]amino]carbonyl]phenyl]methyl]-1,2,3,4-tetrahydro-3-(1-naphthalenyl)-1-oxo-7-isoquinolinyl]-2-chloro- (9CI)
MF C42 H35 Cl N6 O4



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 50 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1,3(2H,4H)-Isoquinolinedione, 7-[[2-[[(1R,2R)-2-aminocyclohexyl]amino]-5-fluoro-4-pyrimidinyl]amino]-4,4-dimethyl- (9CI)
MF C21 H25 F N6 O2

Absolute stereochemistry.



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 50 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzamide, N-(2-amino-2-oxoethyl)-4-[[3,4-dihydro-7-[(4-iodobenzoyl)amino]-1-oxo-3-(3-pyridinyl)-2(1H)-isoquinolinyl]methyl]-N-propyl- (9CI)
MF C34 H32 I N5 O4



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 50 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzamide, N-(2-amino-2-oxoethyl)-4-[[7-[(3-cyclopentyl-1-oxopropyl)amino]-3,4-dihydro-1-oxo-3-(2-pyridinyl)-2(1H)-isoquinolinyl]methyl]-N-(3-pyridinylmethyl)- (9CI)
MF C38 H40 N6 O4

PAGE 1-A





PAGE 1-B



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 50 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Isoquinolinepropanamide, N-(2-amino-2-oxoethyl)-7-[[3,5-bis(trifluoromethyl)benzoyl]amino]-3,4-dihydro-1-oxo-3-(3-pyridinyl)-N-[2-(2-pyridinyl)ethyl]- (9CI)
MF C35 H30 F6 N6 O4





**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 50 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Isoquinolinepropanamide, N-(2-amino-2-oxoethyl)-3,4-dihydro-1-oxo-N-propyl-3-(2-quinolinyl)-7-[(2,3,5,6-tetrafluoro-4-methylbenzoyl)amino]- (9CI)
MF C34 H31 F4 N5 O4



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 50 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzamide, N-(2-amino-2-oxoethyl)-4-[[7-[(2,6-difluorobenzoyl)amino]-3,4-dihydro-1-oxo-3-(3-pyridinyl)-2(1H)-isoquinolinyl]methyl]-N-[2-(2-pyridinylethyl)]- (9CI)
MF C38 H32 F2 N6 O4



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 50 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzamide, N-(2-amino-2-oxoethyl)-4-[[7-[(cyclopentylacetyl)amino]-3,4-dihydro-1-oxo-3-[4-(trifluoromethyl)phenyl]-2(1H)-isoquinolinyl]methyl]-N-(2-methoxyethyl)- (9CI)
MF C36 H39 F3 N4 O5



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 50 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Isoquinolinepropanamide, N-(2-amino-2-oxoethyl)-3,4-dihydro-1-oxo-N-propyl-3-(3-pyridinyl)-7-[(2,3,5,6-tetrafluoro-4-methylbenzoyl)amino]- (9CI)
MF C30 H29 F4 N5 O4



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 50 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzeneacetamide, N-[2-[[4-[[(2-amino-2-oxoethyl)propylamino]carbonyl]phenyl]methyl]-1,2,3,4-tetrahydro-3-(1H-imidazol-2-yl)-1-oxo-7-isoquinolinyl]-3-(trifluoromethyl)- (9CI)
MF C34 H33 F3 N6 O4



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 50 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzamide, N-(2-amino-2-oxoethyl)-4-[[7-[(cyclopentylacetyl)amino]-3,4-dihydro-1-oxo-3-(3-pyridinyl)-2(1H)-isoquinolinyl]methyl]-N-propyl- (9CI)
MF C34 H39 N5 O4



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 50 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Isoquinolinepropanamide, N-(2-amino-2-oxoethyl)-7-[(2-bromobenzoyl)amino]-3,4-dihydro-N-[2-(4-morpholinyl)ethyl]-1-oxo-3-phenyl- (9CI)
MF C33 H36 Br N5 O5



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 50 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN

IN 2(1H)-Isoquinolinepropanamide, N-(2-amino-2-oxoethyl)-7-[(3-cyclopentyl-1-oxopropyl)amino]-3,4-dihydro-1-oxo-N-2-propenyl-3-(2-quinolinyl)- (9CI)
MF C34 H39 N5 O4



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 50 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Isoquinolinepropanamide, N-(2-amino-2-oxoethyl)-7-[[(2-chloro-3-pyridinyl)carbonyl]amino]-N-[3-(diethylamino)propyl]-3-(3,4-difluorophenyl)-3,4-dihydro-1-oxo- (9CI)
MF C33 H37 Cl F2 N6 O4



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 50 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Isoquinolinepropanamide, N-(2-amino-2-oxoethyl)-7-[[2-fluoro-3-(trifluoromethyl)benzoyl]amino]-3,4-dihydro-N-[3-(1H-imidazol-1-yl)propyl]-1-oxo-3-phenyl- (9CI)
MF C34 H32 F4 N6 O4



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 50 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzoic acid, 4-[[3,4-dihydro-7-[[(4-methyl-1,2,3-thiadiazol-5-yl)carbonyl]amino]-3-[4-(methylthio)phenyl]-1-oxo-2(1H)-isoquinolinyl]methyl]-, 2-amino-2-oxoethyl ester (9CI)
MF C30 H27 N5 O5 S2



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L2 50 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 2(1H)-Isoquinolinepropanoic acid, 3-(3-cyanophenyl)-7-[(2-furanylcarbonyl)amino]-3,4-dihydro-1-oxo-, 2-amino-2-oxoethyl ester (9CI)
MF C26 H22 N4 O6



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

ALL ANSWERS HAVE BEEN SCANNED

10/634,473

=> log y

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 0.43 | 0.64 |

STN INTERNATIONAL LOGOFF AT 14:06:32 ON 15 OCT 2005